Skip to main content

Advertisement

SpringerLink
Log in

Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer’s disease in vivo?

  • Controversies-Pro
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

An Erratum to this article was published on 04 March 2005

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992;256(5054):184–5.

    CAS  PubMed  Google Scholar 

  2. Hardy J, Selkoe DJ. Medicine—the amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353–6.

    Article  CAS  PubMed  Google Scholar 

  3. Glenner GG. Amyloid beta protein and the basis for Alzheimer’s disease. Prog Clin Biol Res 1989;317:857–68.

    CAS  PubMed  Google Scholar 

  4. Klein WL, Stine WB Jr, Teplow DB. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer’s disease. Neurobiol Aging 2004;25(5):569–80.

    Article  CAS  PubMed  Google Scholar 

  5. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55(3):306–19.

    Google Scholar 

  6. Ferenci P. Diagnosis and current therapy of Wilson’s disease. Aliment Pharmacol Ther 2004;19(2):157–65.

    Google Scholar 

  7. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Neuron 2003;39:409–21.

    Article  CAS  PubMed  Google Scholar 

  8. Hutton M, McGowan E. Clearing tau pathology with Aβ immunotherapy: reversible and irreversible stages revealed. Neuron 2003;39.

  9. Mann DM, Yates PO, Marcyniuk B. Alzheimer’s presenile dementia, senile dementia of Alzheimer type and Down’s syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol 1984;10(3):185–207.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Building 35, 35 Convent Drive, Room 1A1015 MSC 3707, Bethesda, MD, 20892-3707, USA

    John Hardy

Authors
  1. John Hardy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Hardy.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s00259-004-1758-8

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hardy, J. Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer’s disease in vivo?. Eur J Nucl Med Mol Imaging 31, 1539–1540 (2004). https://doi.org/10.1007/s00259-004-1676-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-004-1676-9

Keywords

Search

Navigation